RA Capital Management and Biotech

Selected healthcare news for the capital firm - RA Capital Management, and the healthcare topic - Biotech. We have 53 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
12/8/2021 Analysis: Top Biotech VC Investors in 2021 Based on Investments at IPO Business Insider Insider analyzed more than 90 IPOs to find the top venture-capital firms that led biotech in 2021. Arch, Novo Holdings, and Flagship Pioneering topped the list with more than $1 billion in equity. Several ... billion in equity: Arch Venture Partners, Novo Holdings, Flagship Pioneering, RA Capital Management, Perceptive Advisors, and SoftBank.Some VCs bet on a range of startups, like RA Capital, which had significant stakes in 18 companies ...
10/6/2021 RA Capital Management, LP Closes $880 Million Venture Capital Fund Globe Newswire BOSTON, RA Capital Management, LP (‚AuRA Capital‚Au) has held a first and final closing of its third venture fund, RA Capital Nexus Fund III, L.P. (‚AuNexus III‚Au). Significantly oversubscribed, Nexus III successfully raised ... alongside its evergreen fund, which invests in public and private biotech companies in accordance with the firm‚Aos primary investment strategy. By expanding the firm‚Aos private investment capabilities, RA Capital can continue to reliably ...
9/27/2021 Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders ... Company"), today announced the closing of a $70 million Series A financing round. The round was led by ARTIS Ventures, RA Capital Management, and founding investor OMX Ventures, with participation from a diverse syndicate of ... investors alike, and continue to attract top neuroscience, chemistry, and biotech talent as we pursue a unique pathway toward treating ‚Ai and potentially healing ‚Ai neuropsychiatric conditions in a new way, at scale," said Mark ...
7/20/2021 Frontier Medicines raises $88M for R&D, including potential rival to Amgen cancer drug - MedCity News MedCity News Amgen received FDA approval earlier this year for a drug that targets a rare mutation once deemed ‚Auundruggable.‚Au Frontier Medicines is going after the same mutation, but the biotech believes its approach offers an edge and it has raised $88.5 million to build its case.The Series B round of funding announced Monday was led by Woodline Partners and RA Capital Management, with equal participation by Deerfield Management Company ...
5/3/2021 Affinia Therapeutics Closes $110 Million Series B Financing Globe Newswire ... Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Existing investors Atlas Venture, F-Prime ... founding the company, we have had the interest of leading biotech investors as well as strategic partners who see the potential of our gene therapy discovery platform to engineer novel vectors that overcome the limitations ...
5/3/2021 Affinia Raises $110 Million to Advance Engineered AAV Gene Therapy Vector Platform ... Capital Management co-led the financing with participation by new investors Avidity Partners, Casdin Capital, GV, Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners. Existing investors Atlas Venture, F-Prime Capital ... founding the company, we have had the interest of leading biotech investors as well as strategic partners who see the potential of our gene therapy discovery platform to engineer novel vectors that overcome the limitations ...
5/3/2021 Affinia Therapeutics Closes $110 Million Series B Financing ... Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Existing investors Atlas Venture, F-Prime ... founding the company, we have had the interest of leading biotech investors as well as strategic partners who see the potential of our gene therapy discovery platform to engineer novel vectors that overcome the limitations ...
4/29/2021 Adcendo raises €51M series A round to pursue 'ideal' ADC target FierceBiotech ... biotech.Ysios, RA Capital Management, HealthCap and Gilde Healthcare have joined with Novo Seeds for the round to support work on a target Adcendo thinks is ideally suited to an ADC approach. The target, uPARAP, is a collagen scavenger receptor that is overexpressed on the cell surface of a range of cancers, including glioblastoma multiforme and triple-negative breast cancer, and restricted to minor subsets of mesenchymal cells in healthy ...
4/29/2021 Ysios Capital leads a ‚Ǩ51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde Ysios Capital leads a ‚C¨51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and GildeADCENDO RAISES ‚C¨51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS.Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company Plans to build a pipeline of ADCs directed at novel cancer targets and ...
4/29/2021 The Ridgway Record COPENHAGEN, Denmark , April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million ( US$ 62 million ) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially ...
4/29/2021 Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers | Markets Insider Business Insider Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company- Plans to build a pipeline of ADCs directed at novel cancer targets and bring lead uPARAP/Endo180 program ... creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII). The new financing, which is the ...
4/19/2021 Adagio adds $336M for pivotal tests of drug with potential to beat Covid variants - MedCity News MedCity News Adagio Therapeutics, a biotech developing antibody therapies that could potentially address the variants the continue to drive the spread of the novel coronavirus, has raised $336 million to conduct a pivotal study of its lead experimental treatment.The new capital, a Series C round of funding, was led by RA Capital Management. It comes nine months after Waltham, Massachusetts-based Adagio launched with science from Adimab, a company that discovers ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Business Wire Business Wire ... RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health Investors Proceeds to be used to advance lead programs in neurodegeneration and cancer Alchemab applies extremely high-throughput antibody sequencing and deep-learning to well-defined patient cohorts to identify naturally-occuring protective antibodies in people who are resilient to disease April 15, 2021 04:00CAMBRIDGE, England- Alchemab Therapeutics, a biotech company developing novel ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics Yahoo News Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health InvestorsProceeds to be used to advance lead programs in neurodegeneration and cancerAlchemab applies extremely high-throughput antibody sequencing and deep-learning to well-defined patient cohorts to identify naturally-occuring protective antibodies in people who are resilient to diseaseAlchemab Therapeutics, a biotech company developing novel products for ...
4/15/2021 The Ridgway Record Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by ...
4/15/2021 Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics Business Wire ... biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors ...
4/15/2021 Alchemab raises 60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Financial Buzz Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by ...
4/15/2021 Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer Rare Daily Staff Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, said it closed an $82 million (£60 million) series A financing round. RA Capital Management led the financing, with participation by an international syndicate that included Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors, and the Dementia Discovery Fund. The company was ...
4/7/2021 Metagenomi Extends Series A Financing to Advance Next-Gen Gene Editing Technology Metagenomi Extends Series A Financing to Advance Next-Gen Gene Editing Technology Rare Daily Staff Gene-editing biotech Metagenomi said it raised $10 million from RA Capital Management in an extension and completion of its series A financing, bringing the round to a total of $75 million. This round, which follows the first close in November 2020, will support the expansion of the Metagenomi team and development of the company ...
4/7/2021 Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic | FierceBiotech FierceBiotech ... biotech is working to overcome the at-scale manufacturing challenges that have held back VLP vaccines so far. The platform supports the design of proteins that self-assemble into VLPs, potentially resulting in vaccines that provide strong, durable protection without causing safety issues.RA Capital Management has stepped up to back Icosavax‚Aos ambitions, leading a $100 million round that also attracted the support of investors including Janus Henderson Investors ...
3/29/2021 After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B FierceBiotech ... licensed two of its antibody-drug conjugate (ADC) candidates, to be known as PYX-201 and PYX-203, to the biotech, while also giving Pyxis a license for its ADC technology platform, including various payload ... co-led by RTW Investments, with help from Perceptive Advisors, RA Capital Management, Pfizer Ventures, and a host of others. This also brings its total funding to date up to $174 million, showing just how ...
3/24/2021 The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping | Markets Insider Business Insider Here's a roundup of top developments in the biotech space over the last 24 hours.(Biotech Stocks Hitting 52-week Highs March 23)(Biotech Stocks Hitting 52-week Lows March 23) Laboratory Corporation of America ... revealed in a series of filings with the SEC that RA Capital Management and Perceptive Advisors bought shares in the company.The stock was up 8.89% to $6 in after-hours trading.Clearside Biomedical, Inc. (NASDAQ ...
3/5/2021 DTx Pharma Closes $100M Series B Financing By FinSMEsDTx Pharma, Inc. , a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing.The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva ...
3/1/2021 DTx Pharma Completes $100M Series B Financing to Advance its FALCON√Ç‚Ñ¢ Platform and Pipeline of RNA Therapeutics DTx Pharma Completes $100M Series B Financing to Advance its FALCON‚N¢ Platform and Pipeline of RNA Therapeutics Proceeds will enable further platform development and accelerate the path toward clinical development Matthew Hammond, Ph.D., Principal at RA Capital Management, and Dan Becker, M.D., Ph.D., Partner at Access Biotechnology, will join DTx Pharma's board of directors SAN DIEGO, March 1, 2021-- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating ...